Page last updated: 2024-12-05

3-hydroxyflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Hydroxyflavone is a natural flavonoid that has been found in a variety of plants, including passionflower, buckwheat, and citrus fruits. It exhibits a range of biological activities, including antioxidant, anti-inflammatory, and anti-cancer properties. Its synthesis involves various chemical reactions, such as condensation and cyclization. It is studied extensively due to its potential therapeutic applications in treating conditions such as inflammation, cancer, and neurodegenerative diseases. Research on 3-hydroxyflavone focuses on understanding its mechanisms of action, optimizing its synthesis and exploring its potential applications in medicine and other fields.'
```

3-hydroxyflavone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11349
CHEMBL ID294009
CHEBI ID5078
SCHEMBL ID20246
MeSH IDM0123037

Synonyms (92)

Synonym
nsc-58585
nsc-58587
nsc-58586
smr000112317
BIDD:ER0553
MLS002207277
3-hydroxy-2-phenylchromone
3-hydroxy-2-phenyl-4h-1-benzopyran-4-one
3-hydroxy-2-phenyl-4h-chromen-4-one
CHEBI:5078 ,
hsdb 7572
unii-ztg9lss5qh
ztg9lss5qh ,
DIVK1C_006927
SDCCGMLS-0066736.P001
nsc-57653
flavon-3-ol
wln: t66 bo evj cr& dq
flavone, 3-hydroxy-
4h-1-benzopyran-4-one, 3-hydroxy-2-phenyl-
flavone,3-hydroxy-
SPECTRUM_000328
SPECTRUM4_001845
einecs 209-416-9
nsc 57653
3-hf
nsc 58585
SPECTRUM5_000350
MEGXP0_001695
ACON1_000167
OPREA1_038914
nsc58585
3-hydroxyflavone
577-85-5
NSC57653 ,
3-hydroxy-2-phenyl-chromen-4-one
EU-0001678
C01495
flavonol
NCGC00095653-01
KBIOSS_000808
KBIO2_000808
KBIO1_001871
KBIOGR_002250
KBIO2_003376
KBIO2_005944
KBIO3_002384
SPECTRUM3_001432
SPBIO_001404
SPECPLUS_000831
SPECTRUM2_001392
SPECTRUM1501012
OPREA1_692205
BSPBIO_003164
H-5000
flavonols ,
3-hydroxyflavone, >=98%
B48D3495-6D21-4742-8A87-D3DE07DC9554
bdbm50187668
KUC106685N
ksc-11-207-16
nci-57653
CHEMBL294009 ,
3-hydroxy-2-phenylchromen-4-one
AKOS000599906
H0379
NCGC00095653-03
NCGC00095653-02
CCG-38858
FT-0615841
3-hydroxyflavone [hsdb]
S4790
F0013-0884
SCHEMBL20246
3-hydroxyflavon
DTXSID4060365
3-hydroxy-2-phenyl-4h-chromen-4-one #
mfcd00006832
VU0053575-3
SR-01000401360-1
sr-01000401360
SR-01000401360-2
3-hydroxy-2-phenyl-4h-1-benzopyran-4-one, 9ci
HY-107825
Q5919049
SY048803
AS-19638
BRD-K55150756-001-05-7
HMS3740M15
D71219
CS-0030701
A869585

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The compounds with a gallate group were more toxic than the corresponding products without one."( Comparative study of the cytotoxicity induced by antioxidant epicatechin conjugates obtained from grape.
Lozano, C; Mitjans, M; Torres, JL; Ugartondo, V; Vinardell, MP, 2006
)
0.33
"Zinc neurotoxicity has been demonstrated in ischemic, seizure, hypoglycemic, and trauma-induced neuronal death where Zn(2+) is thought to be synaptically released and taken up in neighbouring neurons, reaching toxic concentrations."( Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway.
Cai, AL; Sheline, CT; Zipfel, GJ, 2006
)
0.33
" We observed that 150- and 500SiO₂-NP exerted no toxic effects on Calu-3 cells."( Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: protective effects of fisetin.
Corbalan, JJ; Inkielewicz-Stępniak, I; McCarthy, J; Radomski, MW, 2012
)
0.38
" Moreover, hemolysis and cell cytotoxicity testing showed that MPEG-PCL is biocompatible and safe for intravenous injection."( Anti-tumor activity and safety evaluation of fisetin-loaded methoxy poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles.
Chen, X; Chu, B; Deng, X; Guo, G; Liang, J; Liao, J; Long, C; Luo, F; Peng, J; Qian, Z; Sun, J; Xie, C; Yang, Q; Zhang, L, 2014
)
0.4
"Nephrotoxicity is a dose-dependent side effect of cisplatin limiting its clinical usage in the field of cancer chemotherapy."( Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence.
Kalvala, AK; Koneru, M; Kuncha, M; Mahesh Kumar, J; Rachamalla, SS; Sahu, BD; Sistla, R, 2014
)
0.4
" Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin."( Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.
Chang, L; Dai, J; Fu, Y; He, Q; Luo, P; Shao, J; Wang, J; Weng, Q; Yang, B; Yang, X; Zhu, H, 2015
)
0.42
" Nevertheless, there is a clear need for advancing our understanding with regard to safe amounts of intake for these bioactives."( Safety and efficacy of cocoa flavanol intake in healthy adults: a randomized, controlled, double-masked trial.
Balz, M; Ensunsa, JL; Fong, R; Keen, CL; Kimball, J; Kwik-Uribe, C; Momma, TY; Ottaviani, JI; Schroeter, H, 2015
)
0.42
"The aim was to investigate in healthy adults the effects of cocoa flavanol (CF) intake amount and intake duration on blood pressure, platelet function, metabolic variables, and potential adverse events (AEs)."( Safety and efficacy of cocoa flavanol intake in healthy adults: a randomized, controlled, double-masked trial.
Balz, M; Ensunsa, JL; Fong, R; Keen, CL; Kimball, J; Kwik-Uribe, C; Momma, TY; Ottaviani, JI; Schroeter, H, 2015
)
0.42
" Astilbin administration did not lead to death, body weight gain, food consumption, or adverse events."( Nonclinical safety of astilbin: A 4-week oral toxicity study in rats with genotoxicity, chromosomal aberration, and mammalian micronucleus tests.
Fan, X; Gao, Y; Lee, AW; Li, C; Li, G; Li, Y; Liu, Y; Tian, J; Wang, Y, 2017
)
0.46
" We have shown in our earlier studies that gestational administration of 3,3',4',7-Tetrahydroxyflavone or Fisetin reduces the toxic effects of MeHg in the developing rat brain."( Extenuation of in utero toxic effects of MeHg in the developing neurons by Fisetin via modulating the expression of synaptic transmission and plasticity regulators in hippocampus of the rat offspring.
Jacob, S; Sumathi, T, 2019
)
0.51
"The anticancer drug methotrexate (MTX) is known to cause hepatotoxicity as a possibly fatal adverse effect that hinders its clinical application."( Dihydromyricetin alleviates methotrexate-induced hepatotoxicity via suppressing the ‎TLR4/NF-κB pathway and NLRP3 inflammasome/caspase 1 axis.
Awad, EM; El-Sheikh, AAK; El-Tahawy, NFG; Matouk, AI; Waz, S, 2022
)
0.72
" The present study demonstrated the first assessment of the effects of no observed adverse effect concentration (NOAEC) of carbaryl (CR) and acetamiprid (ACE) on transcriptome and metabolome in honeybee larvae reared in vitro."( Combined transcriptome and metabolite profiling analyses provide insights into the chronic toxicity of carbaryl and acetamiprid to Apis mellifera larvae.
Dai, P; Diao, Q; Gao, J; Liu, F; Liu, Y; Ma, S; Wang, Q; Wang, X; Wu, Y; Yang, Y; Zhang, L, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" There was no significant difference in the bioavailability and pharmacokinetic parameters between the onion supplement and quercetin-4'-O-glucoside."( Pharmacokinetics and bioavailability of quercetin glycosides in humans.
Derendorf, H; Drewelow, B; Graefe, EU; Jacobasch, G; Mueller, S; Pforte, H; Riethling, AK; Uehleke, B; Veit, M; Wittig, J, 2001
)
0.31
" Therefore, the objective of the two open phase I clinical trials was to obtain pharmacokinetic data of these constituents from a hypericum extract containing tablet: hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.33
" In the present study, we have investigated the pharmacokinetic profiles of isorhamnetin after oral application in rats equipped with a jugular catheter."( Quantitative determination of isorhamnetin, quercetin and kaempferol in rat plasma by liquid chromatography with electrospray ionization tandem mass spectrometry and its application to the pharmacokinetic study of isorhamnetin.
He, J; Jiang, X; Lan, K, 2007
)
0.34
" Non-compartmental methods were used to perform pharmacokinetic data analysis."( Pharmacokinetics and tissue distribution of a water-soluble flavonol triglycoside, CTN986, in mice.
Guo, J; Meng, F; Ren, Z; Zhao, Y, 2008
)
0.35
" Then we studied the pharmacokinetic characteristics and bioavailability in rats."( Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats.
Cai, BC; Cai, H; Chen, HX; Chen, J; Chen, ZP; Liu, D; Sun, J; Xiao, YY, 2010
)
0.36
" The main pharmacokinetic parameters were as follows: T(1/2z) was 92."( [Study on determination and pharmacokinetics of metabolites from Folium Mori extract in rats].
Jiang, LD; Lou, XF; Xuan, GD; Zhao, L; Zhu, YF, 2011
)
0.37
"The method established in this study is accurate, reliable and reproducible, and can be applied for determination of total quercetin, kaempferol and isorhamnetin in rat plasma after oral administration of FME; the pharmacokinetic studies showed that the distribution of drugs is rapid and elimination is very slow."( [Study on determination and pharmacokinetics of metabolites from Folium Mori extract in rats].
Jiang, LD; Lou, XF; Xuan, GD; Zhao, L; Zhu, YF, 2011
)
0.37
" The method has been successfully applied to a pharmacokinetic study of Oldenlandia diffusa extract after oral administration in rats."( Simultaneous determination of oleanolic acid, p-coumaric acid, ferulic acid, kaemperol and quercetin in rat plasma by LC-MS-MS and application to a pharmacokinetic study of Oldenlandia diffusa extract in rats.
Chen, H; He, S; Huang, X; Li, N; Li, Y; Liu, C; Mi, S; Wang, N; Xu, X; Zheng, X,
)
0.13
"To establish a SPE-HPLC method for analyzing astilbin in rats serum and explore the effects of Yinxieling (YXL) prescription and Smilacis Glabrae Rhizoma on the pharmacokinetic characteristics of effective components."( [Comparative pharmacokinetics study of astilbin after oral administration of Yinxieling prescription or Smilacis Glabrae Rhizoma to rats].
Lu, C; Wang, Y; Zhao, R, 2012
)
0.38
" Significant diffenerce in pharmacokinetic parameter of astilbin including t1/2, Cmax, AUC(0-t), AUC(0-infinity) and MRT were obtained through non-compartment model after oral administration of YXL prescription comparing with Smilacis Glabrae Rhizoma."( [Comparative pharmacokinetics study of astilbin after oral administration of Yinxieling prescription or Smilacis Glabrae Rhizoma to rats].
Lu, C; Wang, Y; Zhao, R, 2012
)
0.38
"The method was applied to a pharmacokinetic study of astilbin."( [Comparative pharmacokinetics study of astilbin after oral administration of Yinxieling prescription or Smilacis Glabrae Rhizoma to rats].
Lu, C; Wang, Y; Zhao, R, 2012
)
0.38
" The validated method was successfully used to pharmacokinetic study in A/J mouse, transport study in the Caco-2 cell culture model, and glucuronidation study using mice liver and intestine microsomes."( Validated LC-MS/MS method for the determination of 3-hydroxflavone and its glucuronide in blood and bioequivalent buffers: application to pharmacokinetic, absorption, and metabolism studies.
Gao, S; Ge, S; Hu, M; Xu, B; Yang, G; Yin, T, 2013
)
0.39
"To establish an LC-MS/MS method for determination of isorhamnetin-3-O-neohesperidoside and investigate its application on pharmacokinetic study in rats."( Analysis of isorhamnetin-3-O-neohesperidoside in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry and its application to pharmacokinetic studies.
Chen, PD; Dai, GL; Ding, AW; Ju, WZ; Liu, SJ; Xie, LY; Xu, J; Yu, BY; Zhou, L, 2013
)
0.39
" The method simultaneously detects bilobalide (BB), ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC), quercetin (QCT), kaempferol (KMF), and isorhamnetin (ISR) for pharmacokinetic study."( Simultaneous determination by UPLC-MS/MS of seven bioactive compounds in rat plasma after oral administration of Ginkgo biloba tablets: application to a pharmacokinetic study.
Chen, YY; Du, PP; Kang, Q; Lan, Y; Li, H; Liu, N; Wang, WP; Wu, Q; Zhang, Q; Zhang, YW; Zhao, BC, 2014
)
0.4
" The plasma concentration profiles and pharmacokinetic parameters were analyzed after oral administration of dextroisomer and racemate DMY at the dose of 100 mg/kg in rats."( Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.
Fang, J; Hou, X; Liu, X; Shi, C; Tong, Q; Wang, W; Xie, X; Xiong, W, 2015
)
0.42
" When co-administrated with single dose of DMY (100 mg/kg), the AUC, Cmax and T1/2 of TP were significantly enhanced by 98, 83 and 66%, respectively."( Dihydromyricetin affect the pharmacokinetics of triptolide in rats.
Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020
)
0.56
"The purpose of this study is to reveal the pharmacokinetic profiles of astilbin with various doses in rats and investigate the oral absolute bioavailability and tissue distribution of astilbin after oral administration."( Pharmacokinetic, bioavailability and tissue distribution study of astilbin in rats.
Shi, M; Xu, M; Yin, L, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" The goal of this study was to elucidate the antitumor effect of the flavonoid, fisetin, combined with the multikinase inhibitor, sorafenib, against human cervical cancer cells in vitro and in vivo."( Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF, 2016
)
0.43
" In the present study, a screening method, using high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (HPLC-Q-TOF-MS) combined with a screening strategy, has been established."( Systematic identification of flavonols, flavonol glycosides, triterpene and siraitic acid glycosides from Siraitia grosvenorii using high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry combined with a screening strategy.
Cheng, P; Huang, P; Liu, XB; Mo, CM; Qing, ZX; Tang, Q; Yang, P; Yang, XY; Zeng, JG; Zhao, H; Zheng, YJ, 2017
)
0.46
"This study illustrated the capacity of the sensitive UHPLC-Q-Exactive mass spectrometer analytical system combined with the data-mining methods to rapidly elucidate the unknown metabolism."( Comprehensive Identification of Astilbin Metabolites in Rats Based on Multiple Metabolite Templates Combined with UHPLC-Q-Exactive Mass Spectrometry.
Dai, L; Dong, F; Dong, P; Jiang, S; Li, H; Wang, S; Yang, A; Zhang, H; Zhang, J, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"We studied the bioavailability and the plasma transport of flavonols in rats fed quercetin or rutin diets."( Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin.
Agullo, G; Demigné, C; Favier, ML; Manach, C; Morand, C; Régérat, F; Rémésy, C; Texier, O, 1995
)
0.29
" Subsequent pharmacokinetic studies with dietary quercetin glycosides showed marked differences in absorption rate and bioavailability."( Absorption, metabolism and health effects of dietary flavonoids in man.
Hollman, PC; Katan, MB, 1997
)
0.3
" Subsequent pharmacokinetic studies with dietary quercetin glycosides showed marked differences in absorption rate and bioavailability."( Bioavailability and health effects of dietary flavonols in man.
Hollman, PC; Katan, MB, 1998
)
0.3
" In the present study, we have investigated the bioavailability of the flavonol quercetin after intravenous and oral application in pigs equipped with a permanent jugular catheter."( Bioavailability and metabolism of the flavonol quercetin in the pig.
Ader, P; Wessmann, A; Wolffram, S, 2000
)
0.31
" Resveratrol is sulphated, and the hepatic and duodenal sulphation might limit the bioavailability of this compound."( Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Spisni, R, 2000
)
0.31
" Glucuronidation may reduce the bioavailability of this compound however, flavonoids inhibit resveratrol glucuronidation and such an inhibition might improve the bioavailability of resveratrol."( Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver.
de Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A, 2000
)
0.31
" However, data on the bioavailability of flavonols from wine are lacking."( Red wine is a poor source of bioavailable flavonols in men.
de Vries, JH; Hollman, PC; Katan, MB; Olthof, MR; van Amersfoort, I, 2001
)
0.31
" We conclude that flavonols are absorbed from tea and that their bioavailability is not affected by addition of milk."( Addition of milk does not affect the absorption of flavonols from tea in man.
Hollman, PC; Katan, MB; Tijburg, LB; Van Het Hof, KH, 2001
)
0.31
" However, data on the bioavailability of quercetin after oral intake are scarce and contradictory."( Pharmacokinetics and bioavailability of quercetin glycosides in humans.
Derendorf, H; Drewelow, B; Graefe, EU; Jacobasch, G; Mueller, S; Pforte, H; Riethling, AK; Uehleke, B; Veit, M; Wittig, J, 2001
)
0.31
" Food sources, dietary intakes, and bioavailability of flavonols are strongly influenced by variations in plant type and growth, season, light, degree of ripeness, food preparation, and processing, all of which are discussed."( Dietary flavonols: chemistry, food content, and metabolism.
Aherne, SA; O'Brien, NM, 2002
)
0.31
" There is growing evidence from human feeding studies that the absorption and bioavailability of specific flavonoids is much higher than originally believed."( Dietary flavonoids: bioavailability, metabolic effects, and safety.
Kasum, CM; Ross, JA, 2002
)
0.31
"We hypothesized that 3',4'-dihydroxyflavonol (DiOHF) by scavenging superoxide anions (O2-*) would increase the bioavailability of NO and potentiate NO-mediated relaxation in the rat aorta."( 3', 4'-dihydroxyflavonol enhances nitric oxide bioavailability and improves vascular function after ischemia and reperfusion injury in the rat.
Chan, EC; Drummond, GR; Woodman, OL, 2003
)
0.32
" These results indicate that co-ingested lipids and emulsifiers could enhance the bioavailability of quercetin glucosides in onion."( Enhancing effect of lipids and emulsifiers on the accumulation of quercetin metabolites in blood plasma after the short-term ingestion of onion by rats.
Azuma, K; Horie, H; Ippoushi, K; Ito, H; Terao, J, 2003
)
0.32
" Elucidation of specific flavonol glycosides in cranberry is significant since the specificity of the sugar moiety may play a role in the bioavailability of the flavonol glycosides in vivo."( Characterization of flavonols in cranberry (Vaccinium macrocarpon) powder.
Guido, JE; Mills, KA; Rosen, RT; Russell, DJ; Vorsa, N; Vvedenskaya, IO, 2004
)
0.32
" The absorption and bioavailability of phenolics in humans are also controversial."( Bioavailability of phenolic compounds.
Karakaya, S, 2004
)
0.32
" The reasons for this are 1) lack of validated in vivo biomarkers, especially in the area of carcinogenesis; 2) lack of long-term studies; and 3) lack of understanding or consideration of bioavailability in the in vitro studies, which are subsequently used for the design of in vivo experiments."( Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies.
Manach, C; Williamson, G, 2005
)
0.33
" The bioavailability of dietary flavonols is discussed with reference to an intervention study with onions, as well as pilot studies with tea, red wine and cherry tomatoes."( Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability.
Aziz, AA; Burns, J; Crozier, A; Edwards, CA; Jenkins, GI; Lean, ME; Rabiasz, HS; Stewart, AJ, 2000
)
0.31
"The objective of these two open phase I clinical trials was the investigation of the bioavailability of five constituents from a hypericum extract containing tablet, which are discussed as the components contributing to the antidepressant action."( Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.33
" In turn, nitric oxide bioavailability deeply influences insulin-stimulated glucose uptake and vascular tone."( Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons.
Desideri, G; Ferri, C; Grassi, D; Lippi, C; Necozione, S, 2005
)
0.33
" The P-gp type efflux pump might limit the bioavailability of Ginkgo flavonols."( Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin.
Cao, J; Wang, Y; Zeng, S, 2005
)
0.33
" A human intervention study was performed to evaluate the bioavailability and antioxidant capacity of (-)-epigallocatechin-3-gallate (EGCG) administered as a single large dose in the form of either purified EGCG or as green tea extract (Polyphenon E)."( Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals.
Carpenter, CL; Hara, Y; Heber, D; Henning, SM; Lee, NH; Liu, Y; Minutti, RR; Niu, Y; Thames, GD; Wang, H, 2005
)
0.33
" The requirement for caution in interpreting these studies is discussed with regard to the limited information available on the bioavailability and biotransformation of these flavonoids."( Flavonols, flavones, flavanones, and human health: epidemiological evidence.
Blumberg, JB; Graf, BA; Milbury, PE, 2005
)
0.33
" The review encompasses the occurrence and bioavailability of the polyphenolics, the in vitro and in vivo evidence for their effects on cancer, both positive and negative, and the various mechanisms by which the chemicals may exert their effects."( A review of the effects and mechanisms of polyphenolics in cancer.
Barney, DL; Exon, JH; Nichenametla, SN; Taruscio, TG, 2006
)
0.33
" Factors that influence the bioavailability of this group of polyphenolic compounds are therefore important."( Red wine alcohol promotes quercetin absorption and directs its metabolism towards isorhamnetin and tamarixetin in rat intestine in vitro.
Bennett, R; Dragoni, S; Gee, J; Sgaragli, G; Valoti, M, 2006
)
0.33
" The bioavailability of flavonoids is influenced by the metabolism of the microflora in the intestine."( Metabolism of quercetin and rutin by the pig caecal microflora prepared by freeze-preservation.
Hein, EM; Humpf, HU; Keppler, K, 2006
)
0.33
" Flavonols at two dosages in oatmeal porridge were rapidly absorbed, and a relatively small amount of sea buckthorn oil added to the porridge seemed to have increased the bioavailability of sea buckthorn flavonols consumed at the higher dose."( Absorption of flavonols derived from sea buckthorn (Hippophaë rhamnoides L.) and their effect on emerging risk factors for cardiovascular disease in humans.
Ahotupa, M; Kallio, H; Suomela, JP; Vasankari, T; Yang, B, 2006
)
0.33
" The advantages of TFH SLNs are the improved oral bioavailability of TFH and the prolonged mean retention time and drug release time."( Preparation and characterization of solid lipid nanoparticles loaded with total flavones of Hippophae rhamnoides (TFH).
Cuia, F; Li, X; Wang, D; Zhao, P,
)
0.13
" Pectin might thus enhance the bioavailability of quercetin from rutin by altering the metabolic activity of the intestinal flora and/or gut physiological function."( Effect of pectin enhancement on plasma quercetin and fecal flora in rutin-supplemented mice.
Hirayama, K; Itoh, K; Nakagawa, H; Tamura, M; Tsushida, T, 2007
)
0.34
" This review summarizes factors influencing the bioavailability of polyphenols, specifically flavanols, flavonols, flavanones, flavones, and hydroxycinnamic (phenolic) acids."( Interactions affecting the bioavailability of dietary polyphenols in vivo.
Scholz, S; Williamson, G, 2007
)
0.34
"As the bioavailability of flavonoids is influenced by intestinal metabolism, we have investigated the microbial deconjugation and degradation of several flavonols and flavonol glycosides using the pig cecum in vitro model system developed in our group."( Deconjugation and degradation of flavonol glycosides by pig cecal microbiota characterized by Fluorescence in situ hybridization (FISH).
Friedrich, AW; Hein, EM; Humpf, HU; Rose, K; van't Slot, G, 2008
)
0.35
"Epidemiological and clinical studies revealed that high-flavanol diet or isolated (-)-epicatechin improves the function of the vascular endothelium, as assessed by flow-mediated dilation, through elevation of bioavailability and bioactivity of NO*."( How do dietary flavanols improve vascular function? A position paper.
Schewe, T; Sies, H; Steffen, Y, 2008
)
0.35
"Although the flavonol quercetin is intensively investigated, our knowledge about its bioavailability and possible target organs is far from being complete."( Tissue distribution of quercetin in pigs after long-term dietary supplementation.
Bieger, J; Blank, R; Cermak, R; de Boer, VC; Hollman, PC; Kamphues, J; Wolffram, S, 2008
)
0.35
" We have analyzed the vasorelaxant effects and the role on NO bioavailability and endothelial function of quercetin and its conjugated metabolites (quercetin-3-glucuronide, isorhamnetin-3-glucuronide and quercetin-3'-sulfate) in rat aorta."( Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta.
Cogolludo, A; Duarte, J; Gonzalez-Paramas, A; Hughes, DA; Jimenez, R; Kroon, PA; Lodi, F; Lopez-Sepulveda, R; Moreno, L; Needs, PW; Perez-Vizcaino, F; Santos-Buelga, C, 2009
)
0.35
" These results indicated that P-glycoprotein and Multidrug Resistance Protein 2 might play important roles in limiting the bioavailability of those compounds."( Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp.
Gao, LB; Liu, T; Meng, MX; Wang, XD; Xu, Q; Zeng, S, 2009
)
0.35
" We conclude that chronic ingestion of high doses of the flavonol quercetin will decrease the bioavailability of simvastatin to a significant extent."( Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs.
Cermak, R; Langguth, P; Wein, S; Wolffram, S, 2009
)
0.35
"Many polyphenolic compounds are poorly digested, and have low bioavailability due to their long chain lengths and chemical composition."( Bioactivity of a flavanol-rich lychee fruit extract in adipocytes and its effects on oxidant defense and indices of metabolic syndrome in animal models.
Fujii, H; Gross, HB; Hackman, RM; Kalgaonkar, S; Keen, CL; Nishioka, H, 2010
)
0.36
" Considering its reported bioavailability and the low dependency of its inhibitory activity on serum dilution, flavonol is likely to be a more effective lysoPLD inhibitor in human blood circulation in vivo than the other inhibitors including LPA."( Evaluation of inhibitory actions of flavonols and related substances on lysophospholipase d activity of serum autotaxin by a convenient assay using a chromogenic substrate.
Fukuzawa, K; Nakao, M; Sano, S; Tanaka, T; Tokumura, A; Ueda, K; Yoshihara, M, 2010
)
0.36
" Emerging bioavailability data is considered and potential molecular mechanisms are evaluated, linking phytochemicals to health effects through their biochemical properties and reactions."( Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability.
Pappas, E; Schaich, KM, 2009
)
0.35
" The findings presented in this work provide evidence concerning the bioavailability of almond skin polyphenols considering the effects of both phase II and microbial metabolism."( Targeted analysis of conjugated and microbial-derived phenolic metabolites in human urine after consumption of an almond skin phenolic extract.
Andrés-Lacueva, C; Bartolomé, B; Garrido, I; Gómez-Cordovés, C; Llorach, R; Martín-Alvarez, PJ; Monagas, M; Urpi-Sarda, M, 2010
)
0.36
"Glucuronidation is often recognized as one of the rate-determining factors that limit the bioavailability of flavonols."( Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model.
Hu, M; Morrow, JK; Singh, R; Wu, B; Zhang, S, 2011
)
0.37
" Hence, our data support that the synthetic 4'-dimethylamino-7,8-dihydroxyflavone and its lead both are orally bioavailable TrkB agonists and possess potent antidepressant effects."( A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect.
Chan, CB; France, S; He, K; Huang, J; Jang, SW; Jia, Y; Liu, X; Luo, HR; Phun, LH; Pradoldej, S; Xiao, G; Ye, K, 2010
)
0.36
"Considering that antioxidant flavonols have been reported to be beneficial to human health, but that their low water solubility and bioavailability limit their administration through systemic route, the development of suitable flavonol-carriers is of great importance for clinical therapeutics."( In vitro evaluation of the antioxidant activity of liposomal flavonols by the HRP-H2O2-luminol system.
Azzolini, AE; Bentley, MV; de Oliveira, CA; Del Ciampo, JO; Kabeya, LM; Landi-Librandi, AP; Lucisano-Valim, YM, 2011
)
0.37
"The main purpose of this research work was to design an optimized self micro-emulsifying drug delivery system (SMEDDS) to enhance the bioavailability of the poor water soluble drug, astilbin."( Optimized self-microemulsifying drug delivery systems (SMEDDS) for enhanced oral bioavailability of astilbin.
Bourkaib, N; Ke, X; Mezghrani, O; Xu, BH, 2011
)
0.37
"Flavanol-rich chocolate (FRC) is beneficial for vascular and platelet function by increasing nitric oxide bioavailability and decreasing oxidative stress."( Cardiovascular effects of flavanol-rich chocolate in patients with heart failure.
Corti, R; Enseleit, F; Flammer, AJ; Hermann, M; Hirt, A; Kaiser, P; Lévêques, A; Lüscher, TF; Noll, G; Périat, D; Ruschitzka, F; Serafini, M; Sudano, I; Thomas, R; Wolfrum, M, 2012
)
0.38
" However, its relatively high EC(50) in cell based assays, low lipophilicity, high topological polar surface area (tPSA), and poor bioavailability suggest that there is room for medicinal chemical improvement."( Chemical modification of the multitarget neuroprotective compound fisetin.
Chiruta, C; Dargusch, R; Maher, P; Schubert, D, 2012
)
0.38
" However, when the fisetin nanoemulsion was administered intraperitoneally, a 24-fold increase in fisetin relative bioavailability was noted, compared to free fisetin."( Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice.
Arnaud, P; Brossard, D; Chabot, GG; Crauste-Manciet, S; Ragelle, H; Scherman, D; Seguin, J, 2012
)
0.38
"The bioavailability of flavanols, anthocyanins and anthocyanin-derived pigments like flavanol-anthocyanin dimers already reported to occur in food products is a major unsolved issue."( On the bioavailability of flavanols and anthocyanins: flavanol-anthocyanin dimers.
de Freitas, V; Fernandes, I; Gonçalves, R; Mateus, N; Nave, F, 2012
)
0.38
" It indicated that the bioavailability of astilbin in YXL enhanced in rats and one of the reasons may be that components of prescription affect the pharmacokinetics of astilbin in vivo."( [Comparative pharmacokinetics study of astilbin after oral administration of Yinxieling prescription or Smilacis Glabrae Rhizoma to rats].
Lu, C; Wang, Y; Zhao, R, 2012
)
0.38
" In vivo, liposomal fisetin allowed a 47-fold increase in relative bioavailability compared to free fisetin."( Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
Bessodes, M; Boyer, R; Brullé, L; Chabot, GG; Lu, YM; Mignet, N; Ramos Romano, M; Scherman, D; Seguin, J; Touil, YS, 2013
)
0.39
"The development of novel neuroprotective compounds to treat acute ischemic stroke (AIS) has been problematic and quite complicated, since many candidates that have been tested clinically lacked significant pleiotropic activity, were unable to effectively cross the blood brain barrier (BBB), had poor bioavailability or were toxic."( Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules.
Lapchak, PA, 2013
)
0.39
" The fisetin-Cys dimer complex showed also higher cytotoxicity to HeLa cells than free fisetin, indicating that the Cys dimer to improve bioavailability of fisetin."( Complexation of fisetin with novel cyclosophoroase dimer to improve solubility and bioavailability.
Cho, E; Choi, JM; Choi, Y; Jeong, D; Jeong, K; Jung, S, 2013
)
0.39
"Slow terminal elimination features of the flavonols counterbalanced the influence of poor oral bioavailability on their systemic exposure levels, which also resulted in significant accumulation of the compounds in plasma during the subchronic treatment with ShuXueNing injection and GBE50."( Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.
Chen, F; Du, F; Li, C; Li, L; Li, X; Ma, X; Sun, Y; Wang, F; Xu, F; Zhang, N; Zhong, C, 2013
)
0.39
" Finally, the challenges of developing flavonoid delivery systems that improve flavonoid bioavailability and their anticancer therapy potentials were summarized."( Delivering flavonoids into solid tumors using nanotechnologies.
Chen, M; Wang, S; Wang, Y; Zhang, J, 2013
)
0.39
"Developed nanocochleates markedly improved anticancer efficacy, bioavailability and safety of fisetin."( Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study.
Bothiraja, C; Pawar, AP; Shaikh, KS; Thorat, UH; Yojana, BD, 2014
)
0.4
" Even within the same subclass, flavonoids may differ considerably in bioavailability and bioactivity."( Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations.
Amiano, P; Boeing, H; Bredsdorff, L; Buijsse, B; Fagherazzi, G; Feskens, EJ; Forouhi, NG; Franks, PW; González, CA; Grioni, S; Guevara, M; Katzke, V; Key, TJ; Khaw, KT; Kühn, T; Langenberg, C; Masala, G; Mattiello, A; Molina-Montes, E; Nilsson, PM; Overvad, K; Perquier, F; Redondo, ML; Riboli, E; Ricceri, F; Rolandsson, O; Romieu, I; Roswall, N; Scalbert, A; Schulze, M; Sharp, SJ; Slimani, N; Spijkerman, AM; Tjonneland, A; Tormo, MJ; Touillaud, M; Tumino, R; van der A, DL; van der Schouw, YT; van Woudenbergh, GJ; Wareham, NJ; Zamora-Ros, R, 2014
)
0.4
" Development of COMT inhibitors can efficiently increase the bioavailability of L-dopa."( Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin.
Jia, YH; Zhu, X, 2014
)
0.4
" The aim of this study was to investigate the oral bioavailability of the flavonol quercetin, applied either as quercetin aglycone (QA) or as its glucorhamnoside rutin (RU), in newborn dairy calves."( Bioavailability of the flavonol quercetin in neonatal calves after oral administration of quercetin aglycone or rutin.
Bruckmaier, RM; Hammon, HM; Kanitz, E; Maciej, J; Schäff, CT; Tuchscherer, A; Wolffram, S, 2015
)
0.42
" Moreover, an in vitro gastrointestinal digestion model, applied to determine the effect of processing on the bioavailability of mulberry antioxidants, indicated a higher anthocyanin bioavailability for the fruit matrix than for the juice matrix."( The effects of juice processing on black mulberry antioxidants.
Beekwilder, J; Boyacioglu, D; Capanoglu, E; Hall, R; Tomas, M; Toydemir, G, 2015
)
0.42
" Its use in the pharmaceutical field is limited due to its poor aqueous solubility which results in poor bioavailability and poor permeability."( Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity.
Chaudhury, K; Chaudhury, S; Dasgupta, S; Ghosh, P; Jana, SK; Singha Roy, A, 2016
)
0.43
" In addition, we provide information regarding the chemistry, sources, bioavailability and clinical impacts of fisetin to provide a broad spectrum for the use of this compound as a new approach to the treatment of AD and PD."( Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine.
Braidy, N; Habtemariam, S; Manayi, A; Nabavi, SF; Nabavi, SM; Sureda, A, 2016
)
0.43
" Processing tomatoes into sauce enhanced the bioavailability of flavanones, flavanols, and some hydroxycinnamic acids, as reflected by the increase in the area under the plasma concentration versus time curve."( Bioavailability of tomato polyphenols is enhanced by processing and fat addition: Evidence from a randomized feeding trial.
Di Lecce, G; Escribano-Ferrer, E; Estruch, R; Illan, M; Jáuregui, O; Lamuela-Raventós, RM; Martínez-Huélamo, M; Tulipani, S; Valderas-Martínez, P; Vallverdú-Queralt, A, 2016
)
0.43
" Increased NO bioavailability improves vasodilation and blood circulation, effects protein kinases, ion channels and phosphodiesterases, counteracting vascular inflammation and LDL oxidative stress."( Polyphenol protection and treatment of hypertension.
Hügel, HM; Jackson, N; May, B; Xue, CC; Zhang, AL, 2016
)
0.43
" the dynamics and flexibility, on the bioavailability of flavonols by using the pivotal biomacromolecule hemoglobin as a model."( Biophysical exploration of protein-flavonol recognition: effects of molecular properties and conformational flexibility.
Ding, F; Peng, W; Peng, YK, 2016
)
0.43
" We identify research areas that need to be addressed to further understand important determinants of flavonoid bioavailability and metabolism and to advance the knowledge base that is required to move toward the development of dietary guidelines and recommendations for flavonoids and flavonoid-rich foods."( The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids.
Cassidy, A; Minihane, AM, 2017
)
0.46
" Therefore, we conclude that the low bioavailability of these flavonoids may be due to their poor stability in the GI tract."( Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation.
Fang, JG; Shi, CY; Wang, CG; Wang, MD; Wang, WQ; Xiang, D; Xiong, W, 2017
)
0.46
" The aim of the present study is to improve the oral bioavailability of FST by encapsulating into PLGA NPs (poly-lactide-co-glycolic acid nanoparticles) as a complex of HPβCD (hydroxyl propyl beta cyclodextrin) and to assess its anti-cancer activity against breast cancer cells."( Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
Bhandi, MM; Borkar, RM; Gudem, S; Kadari, A; Kolapalli, VR; Kulhari, H; Sistla, R, 2017
)
0.46
" We introduce the daily dosage and absorption rate of flavonoids and then focus on their bioactive effects against Cd-induced toxicity and reveal the underlying metabolic pathway, which provides a basis for further study of the nutritional prevention of Cd-induced injury."( Cytoprotective effects of dietary flavonoids against cadmium-induced toxicity.
Bai, W; Jiang, X; Li, X; Liu, L; Sun, J; Tian, L; Zhu, C, 2017
)
0.46
" Our results demonstrate it is possible for phenolic constituents of red wine that are orally bioavailable to exert in vivo hypotensive and antioxidant effects on intact endothelial function."( Antioxidant and Antihypertensive Effects of a Chemically Defined Fraction of Syrah Red Wine on Spontaneously Hypertensive Rats.
Alves, NFB; Braga, VA; Cavalcanti, CO; Figueiredo, EA; Monteiro, MMO; Oliveira, EJ; Silva, TMGD; Silva, TMSD, 2017
)
0.46
" In addition, the increased bioavailability and sustained release of fisetin improved through conjugation and enhanced effect of fisetin through synergism on various cancers are also highlighted."( A review on the chemotherapeutic potential of fisetin: In vitro evidences.
Perumal, E; Raghunath, A; Sundarraj, K, 2018
)
0.48
" Efforts are being made to enhance the bioavailability of fisetin after oral administration to prevent and/or treat cancer of the liver, breast, ovary and other organs."( Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy.
Bishayee, A; Buttar, HS; Kashyap, D; Sak, K; Sharma, A; Tuli, HS, 2018
)
0.48
" The aim of the study was to develop FS loaded pluronic127 (PF)-folic acid (FA) conjugated micelles (FS-PF-FA) by the way of increasing solubility, bioavailability and active targetability of FS shall increase its therapeutic efficacy."( Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting.
Bothiraja, C; Pawar, A; Rajalakshmi, S; Shaikh, K; Singh, S, 2018
)
0.48
"A variety of beneficial pharmacological activities have been reported for dihydromyricetin (DMY), however, its oral bioavailability is poor and the intestinal absorption profiles of DMY remains unknown."( Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells.
Fan, L; Fang, JG; Hou, XL; Shi, CY; Wang, WQ; Xiang, D; Xiong, W, 2018
)
0.48
" DMY was poorly absorbed by a passive diffusion mechanism."( Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells.
Fan, L; Fang, JG; Hou, XL; Shi, CY; Wang, WQ; Xiang, D; Xiong, W, 2018
)
0.48
" 3-O-(N,N-Dibutylamino)propyl-3',4'-dimethoxyflavonol (42) emerged as the most promising derivative due to its substantially improved potency in cell models, superior bioavailability in rats, and good selectivity of inhibiting prostate cancer cell proliferation over non-neoplastic human epithelial cell proliferation."( Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
Chen, G; Chen, QH; Fong, R; Gonzalez, A; Guo, S; Lee, M; Li, X; Rajaram, P; Wang, G; Zhang, C; Zhang, Q; Zheng, S, 2018
)
0.48
" The results suggest that coconsumption GTE or EnzGTE with GTE-derived flavonols could improve the bioavailability of epicatechins."( Impact of Bioconversion of Gallated Catechins and Flavonol Glycosides on Bioaccessibility and Intestinal Cellular Uptake of Catechins.
Balusamy, SR; Choi, EH; Kim, DO; Rha, CS; Shim, SM, 2019
)
0.51
" Despite the vast medicinal importance, their bioavailability is low."( Graphene oxide as selective transporter of flavonols for physiological target DNA: A two-color fluorescence approach.
Coleman, J; Feng, M; Johnson, J; Sengupta, B, 2019
)
0.51
" However, the low oral bioavailability of DMY was one of the special concerns to be resolved for its clinical applications."( Preparation of a nanoscale dihydromyricetin-phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations.
Fan, L; Fang, J; Gong, Y; Lin, T; Shi, C; Wang, W; Yin, M; Zhao, X; Zhou, X, 2019
)
0.51
" However, differences in (poly)phenol profiles and bioavailability likely exist between whole fruit and 100% fruit juice due to processing and the presence/absence of fiber."( Potential health benefits of (poly)phenols derived from fruit and 100% fruit juice.
Ferruzzi, MG; Ho, KKHY; Wightman, JD, 2020
)
0.56
"The purpose of this study is to reveal the pharmacokinetic profiles of astilbin with various doses in rats and investigate the oral absolute bioavailability and tissue distribution of astilbin after oral administration."( Pharmacokinetic, bioavailability and tissue distribution study of astilbin in rats.
Shi, M; Xu, M; Yin, L, 2020
)
0.56
"The oral absolute bioavailability of astilbin is poor because of the low permeability and solubility."( Pharmacokinetic, bioavailability and tissue distribution study of astilbin in rats.
Shi, M; Xu, M; Yin, L, 2020
)
0.56
" However, cocoa polyphenols are poorly absorbed in the intestine, and most of them cannot reach the systemic circulation in their natural forms."( Cocoa Polyphenols and Gut Microbiota Interplay: Bioavailability, Prebiotic Effect, and Impact on Human Health.
Ali, S; Davinelli, S; Mancin, L; Paoli, A; Scapagnini, G; Sorrenti, V, 2020
)
0.56
" As solubility and bioavailability plays and important role in the pharmacological activity, in this research work we tried to improve the oral bioavailability of fisetin."( Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson's disease rat model.
Awasthi, A; Corrie, L; Kapoor, B; Kaur, J; Khurana, N; Khurana, S; Khursheed, R; Kumar, R; Sharma, N; Singh, SK; Verma, S; Vyas, M, 2020
)
0.56
" Compound 3, the most active compound was predicted to be non-toxic, non-mutagenic, has reasonable oral bioavailability and a decent substrate for further drug development."( Flavanols and triterpenoids from Myrianthus arboreus ameliorate hyperglycaemia in streptozotocin-induced diabetic rats possibly via glucose uptake enhancement and α-amylase inhibition.
Adongo, DW; Amponsah, IK; Ben, IO; Dickson, RA; Fleischer, TC; Habtemariam, S; Harley, BK, 2020
)
0.56
" In the present study, their solubility, stability, and bioavailability were compared in a rat."( A Comparison of Solubility, Stability, and Bioavailability between Astilbin and Neoastilbin Isolated from
Ruan, YT; Yin, ZP; Zhang, QF; Zheng, D, 2020
)
0.56
" The bioavailability of DMY in the presence and absence of AA was compared."( Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability.
Li, Y; Sun, CC; Yin, ZP; Zhang, QF, 2021
)
0.62
" The presence of AA could significantly improve the stability of DMY, and further improve its bioavailability in rats."( Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability.
Li, Y; Sun, CC; Yin, ZP; Zhang, QF, 2021
)
0.62
" The extensive metabolism undergone by flavonoids in humans and the individual differences in their bioavailability to target organs hinder the interpretation of results from cell and animal models."( Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease.
Zilli, AMH; Zilli, EM, 2021
)
0.62
" However, its poor aqueous solubility and permeability lead to the low oral bioavailability and limit its clinic application."( Self-Assembled Micelles Improve the Oral Bioavailability of Dihydromyricetin and Anti-Acute Alcoholism Activity.
Bao, S; Li, R; Ren, Q; Xu, X; Ye, J; Zhang, Q; Zhao, S; Zhu, Y, 2021
)
0.62
" The results from the study suggest that formulating green tea extracts rich in catechins with second components obtained from green tea processing could enhance the bioavailability of epicatechins."( Profiling of In Vitro Bioaccessibility and Intestinal Uptake of Flavonoids after Consumption of Commonly Available Green Tea Types.
Chung, JO; Hong, YD; Lee, CY; Lee, YE; Oh, JH; Park, MY; Rha, CS; Shim, SM; Yoo, SH, 2021
)
0.62
" These compounds are widely consumed in daily diet and many studies report several benefits to human health thanks to their bioavailability in humans."( An Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS).
D Amen, E; Dinelli, G; Tibaldi, C; Truzzi, F; Zhang, Y, 2021
)
0.62
" The bioavailability of fisetin in IFM and SSM was measured using the fluorescence method."( FIsetin Preserves Interfibrillar Mitochondria to Protect Against Myocardial Ischemia-Reperfusion Injury.
Boovarahan, SR; Kurian, GA; Prem, PN; Shanmugam, K; Sivakumar, B, 2022
)
0.72
" More clinical trials are necessary to know better their safety, efficacy, delivery and bioavailability in humans, as well as comparative studies with conventional therapies."( Analysis of the Molecular Mechanisms by Flavonoids with Potential Use for Osteoporosis Prevention or Therapy.
Collin, A; de Barboza, GD; Picotto, G; Rivoira, M; Rodríguez, V; Tolosa de Talamoni, N, 2022
)
0.72
" Moreover, in silico pharmacokinetics, pharmacodynamics, and toxicity of fisetin are also comprehensively described along with emerging novel drug delivery strategies for the amelioration of this flavonol bioavailability and chemical stability."( Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection.
Carradori, S; Cataldi, A; Elsallabi, O; Gallorini, M; Patruno, A; Pesce, M, 2022
)
0.72
" Despite having excellent safety and efficacy profile, FS is very less explored to clinical research either as food supplement or, as therapeutic agent due to its poor aqueous solubility, low bioavailability and reduced blood brain barrier permeability."( Harnessing the therapeutic potential of fisetin and its nanoparticles: Journey so far and road ahead.
Adams, J; Awasthi, A; Chellappan, DK; Collet, T; Corrie, L; Devkota, HP; Dua, K; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Khursheed, R; Kumar, R; Loebenberg, R; Porwal, O; Singh, SK; Vishwas, S, 2022
)
0.72
" Therefore, even if the bioavailability is poor, it is often added to daily food, beverages and even medicines."( Recent update on application of dihydromyricetin in metabolic related diseases.
Ding, P; Ji, G; Wang, J; Wang, Y; Wu, T; Xiang, H, 2022
)
0.72
" However, poor water solubility and low bioavailability of kaempferol greatly limit its applications."( Kaempferol: A flavonoid with wider biological activities and its applications.
Bangar, SP; Bansal, V; Chaudhary, V; Lorenzo, JM; Ozogul, F; Sharma, N, 2023
)
0.91
" However, the low water solubility and bioavailability of fisetin restrict its pharmaceutical applications."( Biochemical characterization of synthesized fisetin glucoside by dextransucrase from Leuconostoc mesenteroides NRRL B-1299CB4 with enhanced water solubility.
Kang, CG; Kim, D; Kim, H; Kim, SW; Moon, Y; Park, C, 2022
)
0.72
"Dihydromyricetin (DHM) has garnered attention due to its promising antitumor activity, but its low bioavailability restricts its clinical application."( Pro-Apoptotic Effect of Zeolitic Imidazolate Framework-8 (ZIF-8)-Loaded Dihydromyricetin on HepG2 Cells.
Chen, X; Dong, M; Lou, Y; Lu, J; Mi, X; Zhan, X, 2022
)
0.72
" This is due to their antioxidant and anti-inflammatory properties, despite their low bioavailability which often limits their use in clinical practice."( Flavonoids bridging the gut and the brain: Intestinal metabolic fate, and direct or indirect effects of natural supporters against neuroinflammation and neurodegeneration.
Ceruti, S; Magni, G; Petroni, K; Riboldi, B, 2022
)
0.72
" A synergistic effect with anticancer drugs and strategies to improve the bioavailability are described."( The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment.
Allemailem, KS; Almatroodi, SA; Almatroudi, A; Khan, AA; Rahmani, AH, 2022
)
0.72
" After digestion, different phenolic compounds had different changes of bioavailability and antioxidant activity, which needed to be considered in the application."( Stability and antioxidant activity of phenolic compounds during in vitro digestion.
Deng, ZY; Li, CX; Li, HY; Wang, FR; Zhang, B, 2023
)
0.91
" Thus, novel drug delivery systems are needed to improve solubility and bioavailability of FIS."( Fisetin-loaded grape-derived nanoparticles improve anticancer efficacy in MOLT-4 cells.
Akbarzadelale, P; Gholipour, E; Khodadadi, M; Pourakbari, R; Samadi, P; Sarvarian, P; Shamsasenjan, K, 2023
)
0.91
" The pharmacokinetic study revealed that DHM@GF-DLT could prolong the retention time of DHM, reduce the fluctuation of blood drug concentration, and enhance the bioavailability of DHM."( A double-layered gastric floating tablet for zero-order controlled release of dihydromyricetin: Design, development, and in vitro/in vivo evaluation.
Chen, S; Fu, X; Li, C; Li, S; Liu, H; Shi, H; Shi, J; Tian, Y; Wang, S; Wang, Y; Wu, A; Zhang, C; Zhang, D; Zhang, H; Zhang, R, 2023
)
0.91
" To attain this prospect, some limitations to this molecule, namely its poor bioavailability and solubility, must be addressed."( Fisetin derivatives exhibit enhanced anti-inflammatory activity and modulation of endoplasmic reticulum stress.
Correia da Silva, D; Ferreira, PMT; Jervis, PJ; Martins, JA; Pereira, DM; Valentão, P, 2023
)
0.91
" This study is aimed at preparing chitosan (CS)-based nanoparticles to yield fisetin with improved bioavailability features."( Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis.
Mirmohammadkhani, M; Nabizadeh, Z; Nasrabadi, D; Nasrollahzadeh, M; Shabani, AA, 2023
)
0.91
" However, their low bioavailability makes them complex compounds to use for therapeutic purposes."( Fisetin-In Search of Better Bioavailability-From Macro to Nano Modifications: A Review.
Cielecka-Piontek, J; Szymczak, J, 2023
)
0.91
" This review also describes a growing number of nanodelivery systems designed to improve the bioavailability and solubility of this natural compound."( Role of Fisetin in Selected Malignant Neoplasms in Women.
Antoszczak, M; Huczyński, A; Kacprzak, K; Markowska, A; Markowska, J, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" All flavonoids gave a dose-response relationship and induced a number of AraR mutants considered statistically significant."( Study on the mutagenic activity of 13 bioflavonoids with the Salmonella Ara test.
Alejandre-Durán, E; Alonso-Moraga, A; Jurado, J; Pueyo, C, 1991
)
0.28
"This paper describes a validated high-performance liquid chromatographic (HPLC) - photodiode array (PDA) detection method to quantitate five flavonol components as markers; rutin, quercitrin, quercetin, kaempferol and isorhamnetin for use in the quality control of Ginkgo biloba dosage forms."( High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms.
Dubber, MJ; Kanfer, I, 2004
)
0.32
"A suitable method was developed to identify and quantitate five relevant flavonol marker compounds and was successfully used to assay some commercially available solid oral dosage forms of Ginkgo biloba ."( High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms.
Dubber, MJ; Kanfer, I, 2004
)
0.32
" Concentration/time curves were determined for hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing."( Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.33
"An accurate, precise and sensitive liquid chromatography-tandem mass spectrometric (LC-MS-MS) method was developed for the determination of two flavonol glycosides, rutin and quercitrin, together with the algycone markers, quercetin, kaempferol and isorhamnetin in several Ginkgo biloba solid oral dosage forms."( The simultaneous determination of selected flavonol glycosides and aglycones in Ginkgo biloba oral dosage forms by high-performance liquid chromatography-electrospray ionisation-mass spectrometry.
Dubber, MJ; Kanfer, I; Mshicileli, N; Sewram, V; Shephard, GS, 2005
)
0.33
" These flavonols suppressed intracellular calcium ion elevations in a dose-response manner, with morin being the weakest; they also inhibited phosphorylation of the calcium-insensitive protein kinase C theta (PKC theta)."( Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells.
Boucher, W; Cao, J; Cetrulo, CL; Christodoulou, S; Kempuraj, D; Madhappan, B; Papadopoulou, N; Theoharides, TC, 2005
)
0.33
" Concentration/time curves were determined for the five constituents, for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.33
" This method was used to fingerprint Ginkgo biloba solid oral dosage forms and validated for the quantitation of the marker compounds, rutin and quercetin in some commercial products."( Application of reverse-flow micellar electrokinetic chromatography for the simultaneous determination of flavonols and terpene trilactones in Ginkgo biloba dosage forms.
Dubber, MJ; Kanfer, I, 2006
)
0.33
" After oral dosing of isorhamnetin, the mean values (n = 10) of C(max) were 57."( Quantitative determination of isorhamnetin, quercetin and kaempferol in rat plasma by liquid chromatography with electrospray ionization tandem mass spectrometry and its application to the pharmacokinetic study of isorhamnetin.
He, J; Jiang, X; Lan, K, 2007
)
0.34
" These 8 matrixes consisted primarily of simple dosage forms (e."( Evaluation of a method to determine flavonol aglycones in Ginkgo biloba dietary supplement crude materials and finished products by high-performance liquid chromatography: collaborative study.
Gray, D; LeVanseler, K; Meide, P; Waysek, EH,
)
0.13
" No evidence of dose-response was seen in this experiment."( Dose-related effects of flavanol-rich cocoa on blood pressure.
Berry, NM; Buckley, JD; Coates, AM; Davison, K; Howe, PR; Misan, G, 2010
)
0.36
"C57BL/ 6 mice were randomly divided into 4 groups (n = 8): sham-operated group (Sham), model control group(I/R), low dosage of astilbin treatment group (10 mg/kg) and high dosage of astilbin (40 mg/kg) treatment group."( [Effects of astilbin on the expression of TNF alpha and IL-10 in liver warm ischemia-reperfusion injury].
Ai, QB; Dong, SL; Lin, RK; Mu, N; Wang, QX; Yao, QY; Zhang, CH, 2010
)
0.36
" Heterogeneity was explored by subgroup analyses and univariate meta-regression analysis of several variables including dosage of flavanol content (total or monomers) in chocolate or cocoa products, blinding, baseline blood pressure, theobromine content, sugar content, body-mass-index (BMI), duration and age."( Effect of cocoa on blood pressure.
Fakler, P; Frank, OR; Ried, K; Stocks, NP; Sullivan, TR, 2012
)
0.38
" Therefore, subgroup analysis by duration might be confounded by flavanol dosage used in the control groups, and the level of blinding of participants."( Effect of cocoa on blood pressure.
Fakler, P; Frank, OR; Ried, K; Stocks, NP; Sullivan, TR, 2012
)
0.38
" Furthermore, the duration of benefit and the influence of different dosing regimens remain unclear."( Treatment with quercetin and 3',4'-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo.
Jackson, DE; Linden, MD; Mosawy, S; Woodman, OL, 2013
)
0.39
" The flavonol glycosides occurred as major forms in plasma after dosing with ShuXueNing injection, while the flavonol aglycone conjugates were predominant in plasma after dosing with GBE50."( Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.
Chen, F; Du, F; Li, C; Li, L; Li, X; Ma, X; Sun, Y; Wang, F; Xu, F; Zhang, N; Zhong, C, 2013
)
0.39
" Generalised least-squares trend estimation analysis was used to evaluate dose-response relationships."( Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies.
Liu, J; Ouyang, YY; Wang, X; Zhao, G, 2014
)
0.4
"To establish a method for the determination of astilbin, peoniflorin, rasmarinci acid, isofraxidin and liquiritin contained in Shaolin Xiaoyin tablets, in order to lay a foundation for designing late-stage dosage forms and clinical medication schemes."( [Pharmacokinetic study on peoniflorin, astilbin, rosmarinic acid, isofraxidin and liquiritin in rat blood after oral administration of shaolin xiaoyin tablets].
Feng, LM; Lu, CJ; Wang, YJ; Zhao, RZ, 2014
)
0.4
" At the dosage of 20μg/mL for 1-5, the glucose uptake increasing level was nearly 30%-40% in HepG2 cells."( Hypoglycemic activity evaluation and chemical study on hollyhock flowers.
Chen, Q; Dong, Y; Han, L; Jin, L; Wang, T; Wu, Z; Zhang, Y, 2015
)
0.42
" We introduce the daily dosage and absorption rate of flavonoids and then focus on their bioactive effects against Cd-induced toxicity and reveal the underlying metabolic pathway, which provides a basis for further study of the nutritional prevention of Cd-induced injury."( Cytoprotective effects of dietary flavonoids against cadmium-induced toxicity.
Bai, W; Jiang, X; Li, X; Liu, L; Sun, J; Tian, L; Zhu, C, 2017
)
0.46
" This facilitates their ready acceptance as dietary supplements with no requirements of special dosage and concerns over long-term usage."( Encapsulation of Nutraceutical Ingredients in Liposomes and Their Potential for Cancer Treatment.
Anandharamakrishnan, C; Dutta, S; Moses, JA,
)
0.13
" PRACTICAL APPLICATION: Solid self-emulsifying delivery system (S-SEDS) combined the advantages of liquid self-emulsifying delivery system with those of a solid dosage form to overcome the disadvantages associated with liquid formulations is more convenient for storage and transportation in practical application."( Solid Self-Emulsifying Delivery System (S-SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food.
Huang, J; Ma, Y; Sun, R; Wang, D; Wang, Q; Xia, Q, 2019
)
0.51
"2 mg/kg) with and without DMY in different dosage regimens, then a sensitive and reliable LC-MS/MS method was developed and applied to assess the pharmacokinetics of TP."( Dihydromyricetin affect the pharmacokinetics of triptolide in rats.
Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020
)
0.56
"To examine the dose-response association between the consumption of cocoa flavanols and endothelial function, measured by flow-mediated dilation (FMD)."( Dose-response relationship between cocoa flavanols and human endothelial function: a systematic review and meta-analysis of randomized trials.
Actis-Goretta, L; De Castro, CA; Sun, Y; Zimmermann, D, 2019
)
0.51
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
"5), temperature (25 °C ~ 55 °C) and dosage (39 ~ 72 U/mL PPO and 36 U/mL PPO, 3 ~ 36 U/mL POD)."( Polyphenol oxidase dominates the conversions of flavonol glycosides in tea leaves.
Guo, XY; Liang, YR; Liu, ZY; Lu, JL; Lv, YQ; Ye, JH; Ye, Y; Zheng, XQ, 2021
)
0.62
" A restricted cubic spline regression model was performed for non-linear dose-response analysis."( Flavonoid subclasses and CHD risk: a meta-analysis of prospective cohort studies.
Fan, ZK; Guo, X; Li, D; Li, X; Wang, C; Yang, T, 2022
)
0.72
" DHM (50 and 100 mg/kg) was administered 10-15 min and 2 h postreperfusion followed by daily dosing for 2 more days."( Dihydromyricetin alleviates cerebral ischemia-reperfusion injury by attenuating apoptosis and astrogliosis in peri-infarct cortex.
Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Upadhyay, D; Wasan, H, 2022
)
0.72
" Moreover, the dosage of fisetin and co-morbidities like diabetes and obesity are found to be detrimental factors for cardioprotection."( Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review.
Boovarahan, SR; Kurian, GA; Prem, PN; Sivakumar, B, 2022
)
0.72
" To settle these issues, extensive research has been carried out on its physicochemical properties and dosage forms to produce all kinds of DHM preparations in the past ten years."( Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges.
Liu, H; Shi, H; Zhang, D; Zhang, H; Zhang, R; Zhang, Z, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
NutriBiotic Buffered Meta-C -- 500 mg - 250 CapsuleNutriBioticVitamins & Supplements flavonols, Vitamin C2024-11-29 10:47:42

Drug Classes (2)

ClassDescription
monohydroxyflavoneA hydroxyflavone carrying a single hydroxy substituent.
flavonolsAny hydroxyflavone in which is the ring hydrogen at position 3 of the heterocyclic ring is replaced by a hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00320.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency21.43550.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency28.18380.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency14.21910.316212.443531.6228AID902; AID924
importin subunit beta-1 isoform 1Homo sapiens (human)Potency30.30015.804836.130665.1308AID540253; AID540263
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
snurportin-1Homo sapiens (human)Potency30.30015.804836.130665.1308AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency35.48135.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency89.12510.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.53030.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency16.68680.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency25.11890.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency10.00000.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency15.84890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency15.84890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency10.00000.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)IC50 (µMol)100.00000.03201.46494.8000AID309801
Carbonic anhydrase 12Homo sapiens (human)Ki6.62000.00021.10439.9000AID657374; AID657375
Carbonic anhydrase 1Homo sapiens (human)Ki5.15500.00001.372610.0000AID657368; AID657369
Carbonic anhydrase 2Homo sapiens (human)Ki9.25000.00000.72369.9200AID657370; AID657371
Calmodulin-1Homo sapiens (human)IC50 (µMol)55.20005.17006.81008.0000AID550024
Androgen receptorHomo sapiens (human)IC50 (µMol)23.50000.00000.875310.0000AID429119
Pyruvate kinase PKMHomo sapiens (human)IC50 (µMol)1.75000.50002.788610.0000AID1881921
Pyruvate kinase PKMHomo sapiens (human)Ki3.53003.53003.53003.5300AID1881871
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)73.00000.04002.099810.0000AID309799
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)100.00000.10002.452310.0000AID309798
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)100.00000.00132.81389.8200AID399340
Fatty acid synthaseHomo sapiens (human)IC50 (µMol)100.00000.00772.46245.8000AID270726
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.09000.00130.86969.9000AID1452988
Carbonic anhydrase 9Homo sapiens (human)Ki5.58500.00010.78749.9000AID657372; AID657373
Aurora kinase BHomo sapiens (human)IC50 (µMol)4.29000.00030.96349.8000AID1801097
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Kd10.00000.07305.798110.0000AID615921
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
HSP40, subfamily A [Plasmodium falciparum 3D7]Plasmodium falciparum 3D7AbsAC1000_uM5.37200.12904.116911.3160AID540271
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (352)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
G2/M transition of mitotic cell cycleCalmodulin-1Homo sapiens (human)
regulation of heart rateCalmodulin-1Homo sapiens (human)
detection of calcium ionCalmodulin-1Homo sapiens (human)
G protein-coupled receptor signaling pathwayCalmodulin-1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationCalmodulin-1Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationCalmodulin-1Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumCalmodulin-1Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionCalmodulin-1Homo sapiens (human)
autophagosome membrane dockingCalmodulin-1Homo sapiens (human)
substantia nigra developmentCalmodulin-1Homo sapiens (human)
positive regulation of protein autophosphorylationCalmodulin-1Homo sapiens (human)
regulation of cytokinesisCalmodulin-1Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activityCalmodulin-1Homo sapiens (human)
positive regulation of protein dephosphorylationCalmodulin-1Homo sapiens (human)
cellular response to interferon-betaCalmodulin-1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCalmodulin-1Homo sapiens (human)
regulation of calcium-mediated signalingCalmodulin-1Homo sapiens (human)
positive regulation of cyclic-nucleotide phosphodiesterase activityCalmodulin-1Homo sapiens (human)
response to calcium ionCalmodulin-1Homo sapiens (human)
regulation of cardiac muscle contractionCalmodulin-1Homo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityCalmodulin-1Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activityCalmodulin-1Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activityCalmodulin-1Homo sapiens (human)
cellular response to type II interferonCalmodulin-1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityCalmodulin-1Homo sapiens (human)
regulation of cardiac muscle cell action potentialCalmodulin-1Homo sapiens (human)
organelle localization by membrane tetheringCalmodulin-1Homo sapiens (human)
negative regulation of high voltage-gated calcium channel activityCalmodulin-1Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductionCalmodulin-1Homo sapiens (human)
negative regulation of calcium ion export across plasma membraneCalmodulin-1Homo sapiens (human)
mitochondrion-endoplasmic reticulum membrane tetheringCalmodulin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
osteoblast differentiationFatty acid synthaseHomo sapiens (human)
glandular epithelial cell developmentFatty acid synthaseHomo sapiens (human)
fatty acid metabolic processFatty acid synthaseHomo sapiens (human)
fatty acid biosynthetic processFatty acid synthaseHomo sapiens (human)
inflammatory responseFatty acid synthaseHomo sapiens (human)
ether lipid biosynthetic processFatty acid synthaseHomo sapiens (human)
neutrophil differentiationFatty acid synthaseHomo sapiens (human)
monocyte differentiationFatty acid synthaseHomo sapiens (human)
mammary gland developmentFatty acid synthaseHomo sapiens (human)
modulation by host of viral processFatty acid synthaseHomo sapiens (human)
cellular response to interleukin-4Fatty acid synthaseHomo sapiens (human)
establishment of endothelial intestinal barrierFatty acid synthaseHomo sapiens (human)
fatty-acyl-CoA biosynthetic processFatty acid synthaseHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
proteolysisDipeptidyl peptidase 3Homo sapiens (human)
protein catabolic processDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (121)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
calcium ion bindingCalmodulin-1Homo sapiens (human)
protein bindingCalmodulin-1Homo sapiens (human)
adenylate cyclase activator activityCalmodulin-1Homo sapiens (human)
calcium channel inhibitor activityCalmodulin-1Homo sapiens (human)
protein kinase bindingCalmodulin-1Homo sapiens (human)
titin bindingCalmodulin-1Homo sapiens (human)
protein serine/threonine kinase activator activityCalmodulin-1Homo sapiens (human)
transmembrane transporter bindingCalmodulin-1Homo sapiens (human)
calcium-dependent protein bindingCalmodulin-1Homo sapiens (human)
protein phosphatase activator activityCalmodulin-1Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
RNA bindingFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
protein bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseHomo sapiens (human)
phosphopantetheine bindingFatty acid synthaseHomo sapiens (human)
cadherin bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
fatty acid synthase activityFatty acid synthaseHomo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 3Homo sapiens (human)
protein bindingDipeptidyl peptidase 3Homo sapiens (human)
metalloexopeptidase activityDipeptidyl peptidase 3Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 3Homo sapiens (human)
zinc ion bindingDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (80)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
spindle poleCalmodulin-1Homo sapiens (human)
extracellular regionCalmodulin-1Homo sapiens (human)
nucleusCalmodulin-1Homo sapiens (human)
nucleoplasmCalmodulin-1Homo sapiens (human)
cytoplasmCalmodulin-1Homo sapiens (human)
centrosomeCalmodulin-1Homo sapiens (human)
cytosolCalmodulin-1Homo sapiens (human)
spindle microtubuleCalmodulin-1Homo sapiens (human)
plasma membraneCalmodulin-1Homo sapiens (human)
sarcomereCalmodulin-1Homo sapiens (human)
vesicleCalmodulin-1Homo sapiens (human)
myelin sheathCalmodulin-1Homo sapiens (human)
sperm midpieceCalmodulin-1Homo sapiens (human)
voltage-gated potassium channel complexCalmodulin-1Homo sapiens (human)
protein-containing complexCalmodulin-1Homo sapiens (human)
calcium channel complexCalmodulin-1Homo sapiens (human)
catalytic complexCalmodulin-1Homo sapiens (human)
cytoplasmCalmodulin-1Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
Golgi apparatusFatty acid synthaseHomo sapiens (human)
cytosolFatty acid synthaseHomo sapiens (human)
plasma membraneFatty acid synthaseHomo sapiens (human)
membraneFatty acid synthaseHomo sapiens (human)
melanosomeFatty acid synthaseHomo sapiens (human)
glycogen granuleFatty acid synthaseHomo sapiens (human)
extracellular exosomeFatty acid synthaseHomo sapiens (human)
cytoplasmFatty acid synthaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
cytosolDipeptidyl peptidase 3Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 3Homo sapiens (human)
cytoplasmDipeptidyl peptidase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (148)

Assay IDTitleYearJournalArticle
AID1802643DPP III Enzyme Activity Assay from Article 10.1111/cbdd.12887: \\Validation of flavonoids as potential dipeptidyl peptidase III inhibitors: Experimental and computational approach.\\2017Chemical biology & drug design, 04, Volume: 89, Issue:4
Validation of flavonoids as potential dipeptidyl peptidase III inhibitors: Experimental and computational approach.
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
AID1516858Antifungal activity against Candida glabrata 493 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID487737Antidiabetic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 5 hrs (RVb = -1.17% +/- 8.77%)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID487732Hypoglycemic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 5 hrs (RVb = 1.21+/- 3.64 %)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID1516853Antifungal activity against Candida albicans ATCC 10231 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID657371Inhibition of cytosolic human carbonic anhydrase 2 preincubated for 12 hrs by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID456316ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID596670Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID657370Inhibition of cytosolic human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1631832Inhibition of Trypanosoma brucei PTR1 using H2B as substrate incubated for 10 mins followed by addition of NADPH measured for 10 to 50 mins2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID309802Reductive inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID399340Inhibition of xanthine oxidase assessed as decrease in uric acid production by spectrophotometry1998Journal of natural products, Jan, Volume: 61, Issue:1
Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers.
AID657368Inhibition of cytosolic human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID487731Hypoglycemic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 3 hrs (RVb = 1.39 +/- 5.895 %)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID429129Agonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity at 100 uM by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID671220Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1516850Antifungal activity against Candida albicans 501 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID456318DPPH radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1516847Antifungal activity against Candida parapsilosis 96 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID339057Inhibition of Moloney murine leukemia virus reverse transcriptase using (ribocytidylic acid)n(deoxyguanylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID270727Inhibition of FAS at 100 uM2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
AID429128Agonist activity at androgen receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity at 100 uM by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID332645Inhibition of calf thymus DNA topoisomerase 1 catalytic domain-mediated supercoiled Escherichia coli pUC8 DNA relaxation up to 100 uM after 30 mins by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID671213Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID265762Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID487896Antidiabetic activity in STZ-induced Wistar rat assessed as reduction in blood glucose level at 50 mg/kg, ig after 1 day relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID188853Percent protection from gastric damage in rats relative to vehicle control following intraperitoneal administration of 20 mg/Kg1995Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25
Synthesis and biological evaluation of substituted flavones as gastroprotective agents.
AID487898Antidiabetic activity in STZ-induced Wistar rat assessed as reduction in blood glucose level at 50 mg/kg, ig after 3 day relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID768688Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A up to 10 uM preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID319894Antioxidant activity in Sprague-Dawley rat thoracic aorta assessed as superoxide levels at 10 uM by lucigenin-enhanced chemiluminescence assay relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1516854Antifungal activity against Candida glabrata 507 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1424434Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-15, Volume: 142Recent discoveries of anticancer flavonoids.
AID671217Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID339056Inhibition of Moloney murine leukemia virus reverse transcriptase using (riboadenylic acid)n(deoxythymidylic acid)12-18 as template primer by liquid scintillation counting1992Journal of natural products, Feb, Volume: 55, Issue:2
Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity.
AID487730Hypoglycemic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 1 hr (RVb = 10.96 +/- 3.67 %)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID1516855Antifungal activity against Candida glabrata 531 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1516856Antifungal activity against Candida glabrata 587 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID404013In vivo antitumor activity against mouse P388 cells
AID309801Inhibition of 15-hLO22007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID332929Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID404070In vivo antitumor activity against mouse CA-755 cells
AID657374Inhibition of transmembrane tumor-associated human carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID1516851Antifungal activity against Candida albicans 498 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID379054Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID309799Inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID487736Antidiabetic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 7 hrs (RVb = -10.51% +/- 5.53%)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID615921Binding affinity to ABCB1 nucleotide binding domain 22011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.
AID550022Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins relative to control2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID596668Cytotoxicity in in mouse 3T3L1 cells assessed as reduction in triglyceride accumulation at 30 uM2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID657373Inhibition of transmembrane tumor-associated human carbonic anhydrase 9 preincubated for 12 hrs by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID319895Antioxidant activity in Sprague-Dawley rat thoracic aorta assessed as superoxide levels at 10 uM by NBT assay relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID265763Inhibition of FabZ at 100 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID309798Inhibition of 12-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID657369Inhibition of cytosolic human carbonic anhydrase 1 preincubated for 12 hrs by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID265765Inhibition of FabG at 100 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID487733Hypoglycemic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 7 hrs (RVb = -3.59 +/- 2.65 %)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID332930Cytotoxicity against human H9 cells after 3 days1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID596673Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 30 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID550021Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID270726Inhibition of FAS2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
AID487734Antidiabetic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 1 hr (RVb = 20.18 % +/- 8.49%)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID1881921Inhibition of PKM2 (unknown origin) Gly128, Hie78, Hie84, Lys207, Asp177, Lys367, Ile51 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1891749Binding affinity to recombinant His-tagged full length human PDI-b' x domain substrate binding pocket expressed in Escherichia coli BL21 (DE3) cells assessed as decrease in fluorescence intensity at 100 uM incubated for 10 mins by tryptophan fluorescence 2022Journal of natural products, 05-27, Volume: 85, Issue:5
Identification of Antithrombotic Natural Products Targeting the Major Substrate Binding Pocket of Protein Disulfide Isomerase.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID654747Inhibition of GST-tagged Human papillomavirus 16 protein E6 interaction with His-tagged human caspase 8 expressed in Escherichia coli at 20 nM to 20 uM after 1 hr incubation followed by overnight incubation by Alpha screening technique2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.
AID605243Agonist activity at TrkB in E17 rat primary cortical neurons assessed as AKT phosphorylation at Ser 473 at 500 nM after 15 mins by ELISA2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect.
AID550023Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins relative to control2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID429119Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID332931Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B1994Journal of natural products, Jan, Volume: 57, Issue:1
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.
AID487735Antidiabetic activity in Wistar rat assessed as change in blood glucose level at 50 mg/kg, ig after 3 hrs (RVb = -9.83 % +/- 5.67%)2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID550024Inhibition of human recombinant calmodulin assessed as inhibition of calmodulin-sensitive cAMP phosphodiesterase activation after 15 mins by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID404008Cytotoxicity against human KB cells
AID487900Antidiabetic activity in STZ-induced Wistar rat assessed as reduction in blood glucose level at 50 mg/kg, ig after 5 day relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID319893Vascular activity in KPSS precontracted Sprague-Dawley rat thoracic aorta assessed as endothelium dependent relaxation2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID671218Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID515157Antimutagenic activity in Salmonella Typhimurium TA98 assessed as inhibition of 3-nitrofluoranthene-induced mutation by Ames test2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Multivariate QSAR study on the antimutagenic activity of flavonoids against 3-NFA on Salmonella typhimurium TA98.
AID596672Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID404067In vivo antitumor activity against mouse S180 cells
AID404012In vivo antitumor activity against mouse LLC cells
AID550020Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID657372Inhibition of transmembrane tumor-associated human carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID265761Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1881871Binding affinity to PKM2 (unknown origin) assessed as oxidation of beta-NADH by spectrophotometry based LDH coupled assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID487899Antidiabetic activity in STZ-induced Wistar rat assessed as reduction in blood glucose level at 50 mg/kg, ig after 4 day relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID1516852Antifungal activity against Candida albicans 53 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID379055Cytotoxicity against human monocytes assessed as depletion of cellular LDH activity1999Journal of natural products, Mar, Volume: 62, Issue:3
Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes.
AID1167300Antioxidant activity assessed as DPPH radical scavenging activity incubated at room temperature for 20 mins by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Design, synthesis and exploring the quantitative structure-activity relationship of some antioxidant flavonoid analogues.
AID1516859Antifungal activity against Candida glabrata 482 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID1516849Antifungal activity against Candida krusei 168 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID657375Inhibition of transmembrane tumor-associated human carbonic anhydrase 12 preincubated for 12 hrs by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins.
AID768690Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 up to 10 uM preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1265118Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate at 20 uM incubated for 15 mins by HPLC method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1516848Antifungal activity against Candida tropicalis 166 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID404069In vivo antitumor activity against mouse L1210 cells
AID429118Antagonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as inhibition of Dex-induced luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID399341Antioxidant activity assessed as superoxide-scavenging activity by nitrite method1998Journal of natural products, Jan, Volume: 61, Issue:1
Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers.
AID487897Antidiabetic activity in STZ-induced Wistar rat assessed as reduction in blood glucose level at 50 mg/kg, ig after 2 day relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.
AID390723Inhibition of HSL in Wistar rat isolated fat cells at 1 uM by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID1891750Binding affinity to recombinant His-tagged full length human PDI-b' x domain substrate binding pocket expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition constant at 100 uM incubated for 10 mins by tryptophan fluorescence based assay2022Journal of natural products, 05-27, Volume: 85, Issue:5
Identification of Antithrombotic Natural Products Targeting the Major Substrate Binding Pocket of Protein Disulfide Isomerase.
AID1516857Antifungal activity against Candida glabrata 510 by microdilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID596671Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID332646Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting up to 100 uM by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID265764Inhibition of FabI at 100 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID319896DPPH scavenging activity in Sprague-Dawley rat thoracic aorta at 100 uM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID34491The compound was tested for Inhibitory effect uM1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.
AID759072Cytotoxicity against human HCT116 cells assessed as cell viability at 15 uM after 48 hrs by MTT assay relative to control2013European journal of medicinal chemistry, Jul, Volume: 65Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin.
AID404009In vivo antitumor activity against mouse B16 carcinoma cells
AID309800Selectivity for 12h-LO over 15-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID671219Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1452988Inhibition of human CYP1B1 expressed in Escherichia coli DH5alpha coexpressing human NADPH P450 reductase using 7-ethoxyresorufin as substrate in presence of NADP+ by spectrofluorometeric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID456319ABTS radical scavenging activity assessed as vitamin C equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID550025Ratio of chlorpromazine IC50 to compound IC50 for human recombinant calmodulin2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,551)

TimeframeStudies, This Drug (%)All Drugs %
pre-199079 (2.22)18.7374
1990's170 (4.79)18.2507
2000's904 (25.46)29.6817
2010's1737 (48.92)24.3611
2020's661 (18.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.88 (24.57)
Research Supply Index8.23 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index41.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials84 (2.30%)5.53%
Reviews212 (5.80%)6.00%
Case Studies1 (0.03%)4.05%
Observational4 (0.11%)0.25%
Other3,356 (91.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]